In the spring of 1884, a 28-year-old Viennese neurologist named Sigmund Freud published “Über Coca,” a superb medical analysis of cocaine hydrochloride.1 - 2 Although the monograph was an early career milestone for the ambitious physician, it also represented a missed opportunity. Using himself as his experimental subject over several months, Freud consumed a great deal of cocaine as he recorded the drug's physiological effects and potential therapeutic uses. However, he skimmed over cocaine's most important clinical use as a local anesthetic. In a hurried last paragraph, a postscript really, Freud noted that “cocaine and its salts have a marked anesthetizing effect when brought into contact with the skin and mucous membrane in concentrated solution.” Without offering any additional data or experiments, Freud merely concluded that these properties “should make it suitable for a good many applications.”2
The person who did capitalize on describing cocaine's anesthetic properties was Freud's colleague Carl Koller, an aspirant (intern) in ophthalmology at the Vienna Allgemeines Krankenhaus (General Hospital).3 That Koller became so interested in local anesthesia was a direct result of the operation he frequently performed: cataract removal. Although practiced since antiquity, it remained a dreaded procedure in 1884. After all, without pharmaceutical assistance, cataract removal was not only excruciating, it required a patient to watch as the surgeon, literally, poked him or her in the eye. Few have re-created the operation's awful immediacy as well as the British novelist Thomas Hardy: “It was a like a red-hot needle in yer eye while he was doing it. But he wasn't long about it. Oh No. If he had been long I couldn't ha’ beared it. He wasn't a minute more than three quarters of an hour at the outside.”4
With the advent of ether and chloroform in the mid-19th century came great hopes among ophthalmologists for making cataract removal less traumatic. But these anesthetic agents often induced vomiting in patients—which in turn created alarmingly high pressures in the abdomen, chest, and head that are not conducive to performing delicate eye surgery.
During the summer of 1884, Koller slaved over a formal address on cocaine for the international Ophthalmological Congress to be held that September at Heidelberg. Too poor to afford the travel expenses to Germany, he asked Josef Brettauer, a 49-year-old ophthalmologist, to read his paper at the meeting—a common practice in an era when travel was both costly and arduous. The presentation was nothing short of spectacular.
As the world's most distinguished eye surgeons took their seats in the auditorium, Brettauer approached the podium. After explaining what Koller had been working on for the past few months, Koller's surrogate snapped his fingers and called for a diener to wheel in a gurney bearing a large dog. With a theatrical flair, the physician showed the audience that the animal was alert, comfortably seated on a cushion, and loosely tied down on the gurney.
He then took a calibrated dropper full of cocaine solution, delicately held the canine's left eye open with his thumb and forefinger, and introduced 3 or 4 drops of the elixir. Brettauer let 1, then 2, minutes pass in silence—a period that seems like a lifetime when giving a lecture before a crowded room. Satisfied that the cocaine had taken effect, he thrust a forceps toward the dog's eye. While the animal's right eye blinked in response to this threat, the left eye remained still. Brettauer deftly touched the canine's left eye with the surgical instrument and the results were astonishing: nothing happened! No whimpering, no barking, not even a flinch—that is, until the crowd sighed in relief that no harm had come to the dog and burst into uproarious applause.5
The development of a topical agent that could safely render a patient insensate to the surgeon's pointedly sharp manipulations while completely awake was earthshaking. It was front-page news that captured the attention of just about every physician (and dentist) in the world. It also enabled pharmaceutical companies to make a fortune marketing cocaine and, later, safer local anesthetics like procaine hydrochloride (Novocain) and lidocaine hydrochloride (Xylocaine).
Freud, understandably, was less than thrilled about Koller's achievement. Working in the same hospital, where gossip of successes and failures traveled quickly, could not have been an easy cross for the young, sensitive physician to bear. Whenever the topic of cocaine came up, it was Koller's name and not Freud's that generated adulation.
Initially, the jealous Freud claimed that he and Leopold Königstein, a Viennese ophthalmologist, were already working on cocaine anesthesia and that it was Freud who introduced the idea to Koller; few bought such claims. Months later, in January 1885, he dismissively declared that his cocaine work was merely a scientific trifle he executed in the “chase after money, position and reputation.”6 Another barometer of Freud's feelings about his scientific rival can be summarized by his later contention that a joke is never really a joke.7 In 1885, Freud inscribed a copy of his “Über Coca” for Carl Koller: “To my dear friend, Coca Koller, from Sigmund Freud”—a mildly demeaning sobriquet that, much to the ophthalmologist's chagrin, followed Koller well after his death in 1944.8
Nor did it end there. In 1895, Freud experienced a dream in which he received due credit for the “discovery” of cocaine. It occurred around the time when Freud had arranged for his father to undergo surgery for glaucoma with the benefit of cocaine anesthesia. In 1900, he reported in The Interpretation of Dreams that during this particular dream, Koller congratulated both him and Königstein for being members of the medical triumvirate who introduced local anesthesia to the world.9 The dream may have been based on a real experience or, more likely, was merely a wish.
Even 40 years after the event, while musing over this period of his life in his 1925 autobiography, Freud went as far as to blame Martha, his then-fiancée and now wife, for distracting him from his cocaine experiments.10
It hardly required the genius of a Freud to inquire why touching his tongue and lips with cocaine created such powerfully numbing sensations; this is, after all, a key characteristic of ingesting it. With his frequent cocaine use, it is difficult to explain why he did not value this particular action of the drug as much as he did its ability to alter one's mood, blood pressure, breathing rate, and many other physiological and sensational parameters. Perhaps Freud was so preoccupied with completing his paper and rushing it into print that he simply neglected this particular drug action. Maybe his lack of interest in pain-inducing, surgical procedures blocked his view to such a critical finding. An even more possible explanation might be that the exhilarating effects of cocaine—the high rather than the physical numbness—dominated his thoughts and actions. Whatever the reason, he made a colossal blunder by overlooking what proved to be a historic scientific discovery.
The annals of medical history, of course, are littered with tales of investigators bested by others in the aggressive quest for discovery. The striking difference in this case was that Freud had the talent and determination to transcend his early defeat. Only a few years later he would unveil his own signature discoveries of psychoanalysis and “the talking cure.”
Corresponding Author: Howard Markel, MD, PhD, Center for the History of Medicine, University of Michigan Medical School, 100 Simpson Memorial Institute, Box 0725, 102 Observatory, Ann Arbor, MI 48109-0725 (howard@umich.edu).
Conflict of Interest Disclosures: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Markel reported that he is the author of a forthcoming book, An Anatomy of Addiction: Sigmund Freud, William Halsted, and the Miracle Drug Cocaine, which will be published by Pantheon Books in July 2011 and from which he drew some of the research for this article. No other disclosures were reported.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.